Home › Funds › Rosalind Advisors, Inc. › OVID
Rosalind Advisors, Inc. position in OVID
OVID THERAPEUTICS INC · Health Care
Rosalind Advisors, Inc. reported holding 1,107,994 shares of OVID (OVID THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$3.0M, representing 1.11% of its reported portfolio and ranking #18 among its reported holdings. Rosalind Advisors, Inc. has disclosed OVID holdings in 3 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Rosalind Advisors, Inc.'s OVID position evolved
Rosalind Advisors, Inc. first disclosed a stake in OVID in Q2 2025 at 500,000 shares (US$165K). The position peaked in Q2 2026 at 1,107,994 shares, worth US$3.0M. Across 3 filings, Rosalind Advisors, Inc. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,107,994 shares valued at US$3.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 500.00K | $164.95K | New |
| Q1 2026 | 1.11M | $2.46M | New |
| Q2 2026 | 1.11M | $2.98M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OVID and 13F data
OVID (OVID THERAPEUTICS INC) is a Health Care company. 52 other funds we track also report a position in OVID — the largest reported positions include Affinity Asset Advisors, LLC (US$27.3M), ADAR1 Capital Management, LLC (US$20.0M), SILVERARC CAPITAL MANAGEMENT, LLC (US$8.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OVID
- Affinity Asset Advisors, LLC 10.14M sh · $27.29M · Q2 2026
- ADAR1 Capital Management, LLC 7.42M sh · $19.95M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.10M sh · $8.34M · Q2 2026
- STEMPOINT CAPITAL LP 2.42M sh · $6.50M · Q2 2026
- Ikarian Capital, LLC 2.27M sh · $6.11M · Q2 2026
- Propel Bio Management, LLC 1.12M sh · $3.00M · Q2 2026
- Sio Capital Management, LLC 1.01M sh · $2.70M · Q2 2026
- Saturn V Capital Management LP 663.06K sh · $1.78M · Q2 2026
- Ally Bridge Group (NY) LLC 624.56K sh · $1.68M · Q2 2026
More on Rosalind Advisors, Inc.
FAQ
How long has Rosalind Advisors, Inc. held OVID?
Rosalind Advisors, Inc. has disclosed OVID holdings in 3 of the last 5 reported quarters, going back to Q2 2025.
What is Rosalind Advisors, Inc.'s current position in OVID?
As of Q2 2026, Rosalind Advisors, Inc. holds 1.11M shares of OVID (OVID THERAPEUTICS INC), valued at $2.98M, representing 1.11% of its reported portfolio and ranking #18.
Has Rosalind Advisors, Inc. been buying or selling OVID?
In the latest 13F filing (Q2 2026), Rosalind Advisors, Inc. held unchanged its position in OVID. The position peaked in Q2 2026 at 1.11M shares.
Which other funds hold OVID?
Other major institutional holders of OVID include Affinity Asset Advisors, LLC, ADAR1 Capital Management, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.